Dose-Escalation Stereotactic Ablative Radiotherapy for Ultra-Elderly Bladder Cancer
NCT07930910, Completed, Peking University First Hospital
Trial 9
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
| Field | Value | Source |
|---|---|---|
| Title | Dose-Escalation Stereotactic Ablative Radiotherapy for Ultra-Elderly Bladder Cancer | ClinicalTrials.gov |
| NCT number | NCT07930910 | ClinicalTrials.gov |
| Status | Completed | ClinicalTrials.gov |
| Enrollment | 13 participants, actual | ClinicalTrials.gov |
| Lead sponsor | Peking University First Hospital | ClinicalTrials.gov |
| Conditions | Bladder Cancer | ClinicalTrials.gov |
| Interventions | Dose Level 1, Dose Level 2, Dose Level 3, Dose Level 4 | ClinicalTrials.gov |
| First posted | 2026-11-12 | ClinicalTrials.gov |
| Last updated | 2026-11-12 | ClinicalTrials.gov |
Registered outcomes 6
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description | Source |
|---|---|---|---|---|
| Primary | Maximum tolerated dose (MTD) of five-fraction SABR | Up to 7 months after completion of SABR | Description: The MTD is the highest dose level at which no more than one of three, or one of six, participants has a dose-limiting toxicity (DLT). A DLT is any radiotherapy-related adverse event of Grade 3 or higher (NCI CTCAE v5.0) occurring within 7 months after completion of SABR. | ClinicalTrials.gov |
| Secondary | Acute radiotherapy-related toxicity | Up to 3 months after completion of SABR | Number of participants with radiotherapy-related adverse events graded with NCI CTCAE v5.0, from the start of SABR to 3 months after completion of SABR. | ClinicalTrials.gov |
| Secondary | Late radiotherapy-related toxicity | From 3 months to 24 months after completion of SABR | Number of participants with radiotherapy-related adverse events graded with NCI CTCAE v5.0, occurring more than 3 months after completion of SABR | ClinicalTrials.gov |
| Secondary | Symptomatic response rate | At 3-month intervals, assessed up to 24 months | The percentage improvement in cancer-related symptoms (hematuria, frequency, dysuria) | ClinicalTrials.gov |
| Secondary | Local recurrence (LR) | At 3-month intervals, assessed up to 24 months | defined as an enlarging lesion within the PTV defined by RECIST 1.1 criteria | ClinicalTrials.gov |
| Secondary | Overall Survival (OS) | From the start of SABR treatment until the date of death or last follow-up (assessed up to 2 years). | Overall survival is defined as the time from the date of the first fraction of SABR to the date of death from any cause. For patients who remain alive at the time of the last follow-up, survival time will be censored at the date of the last contact. | ClinicalTrials.gov |
Outcomes 0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
| Type | Outcome | Time frame | Population | Units | Measured as | Source |
|---|
Results by group 0
Each measurement the trial posted, group by group, in the words and numbers it posted.
| Outcome | Group | Category | Value | Spread | Units | Source |
|---|
Participant flow 0
How many started, completed or left each group, period by period.
| Period | Milestone | Group | Participants | Units counted | Source |
|---|
Adverse events 0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
| Type | Event | Organ system | Group | Affected | At risk | Events | Source |
|---|
Adverse event totals 0
The totals the trial posted for each group.
| Total | Group | Affected | At risk | Source |
|---|
Papers 0
The papers the trial lists on ClinicalTrials.gov.
| PMID | Listed as | Source |
|---|
Trial comparisons 0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
| Comparison | Source |
|---|
Tests 0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
| Test | Named as | Source |
|---|
Source 4
| Field | Value | Source |
|---|---|---|
| Release | trials-2026-11-12-0.3.0 | ClinicalTrials.gov |
| Release manifest SHA-256 | 4a570df2e7274cee2d4fa2959402fab41880e2cd412e4b590390035fbea69391 | ClinicalTrials.gov |
| Registry capture | 2026-11-12 | ClinicalTrials.gov |
| Results copy, AACT | 2026-03-23 | ClinicalTrials.gov |
Release trials-2026-11-12-0.3.0
ClinicalTrials.gov's posted results, through CTTI's AACT: ClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299 ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
ClinicalTrials.gov: none stated ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.